The estimated Net Worth of Jean Pierre Bizzari is at least 6.44 百万$ dollars as of 17 June 2024. Jean Bizzari owns over 6,995 units of Halozyme Therapeutics stock worth over 4,721,624$ and over the last 10 years he sold HALO stock worth over 1,455,566$. In addition, he makes 260,002$ as Independent Director at Halozyme Therapeutics.
Sign up
Jean Bizzari HALO stock SEC Form 4 insiders trading
Jean has made over 2 trades of the Halozyme Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 6,995 units of HALO stock worth 20,216$ on 17 June 2024.
The largest trade he's ever made was selling 35,000 units of Halozyme Therapeutics stock on 25 August 2021 worth over 1,435,350$. On average, Jean trades about 2,210 units every 54 days since 2015. As of 17 June 2024 he still owns at least 79,502 units of Halozyme Therapeutics stock.
You can see the complete history of Jean Bizzari stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Jean-Pierre Bizzari biography
Dr. Jean-Pierre Bizzari, M.D. is an Independent Director of the Company. Dr. Bizzari provides our Board of Directors with over 30 years of clinical oncology and global drug approval strategy expertise. He retired from Celgene Corporation having served as Executive Vice President and Global Head of Oncology from October 2012 to December 2015 and as Senior Vice President for Clinical Development Oncology from 2008 to October 2012, and oversaw the development and approval of a number of leading oncology products including REVLIMID® (lenalidomide), VIDAZA® (azacitidine), ISTODAX® (romidepsin) and ABRAXANE® (nab-paclitaxel). Prior to 2008, Dr. Bizzari served as Vice President, Clinical Oncology Development for Sanofi-Aventis where he oversaw the approval of Eloxatin® (oxaliplatin), Taxotere® (docetaxel) and Elitek®(rasburicase). Dr. Bizzari was also Vice President, Clinical Development Oncology for Rhône-Poulenc Rorer. Dr. Bizzari is a member of the Scientific Advisory Board of France’s National Cancer Institute. Dr. Bizzari has also been a member of the international scientific committee of the French National Cancer Research Institute since 2005 and the French National Cancer Institute (INCa) since 2010. Dr. Bizzari also serves on the board of directors of Transgene SA, a biopharmaceutical company, and biotechnology companies Compugen Ltd., Pieris Pharmaceuticals, Inc. and Nordic Nanovector ASA. Within the past five years he also served on the board of directors of Celator Pharmaceuticals, Inc., a biopharmaceutical company, and iTeos Therapeutics S.A, a biotechnology company. He also serves as a board observer at Onxeo S.A. Dr. Bizzari is a Doctor of Medicine and a graduate of the Nice Medical School and a specialist in oncology (training in Toronto and Montreal). Dr. Bizzari was also an assistant in the medical oncology department at La Pitié-Salpêtrière hospital in Paris.
What is the salary of Jean Bizzari?
As the Independent Director of Halozyme Therapeutics, the total compensation of Jean Bizzari at Halozyme Therapeutics is 260,002$. There are 9 executives at Halozyme Therapeutics getting paid more, with Helen Torley having the highest compensation of 5,857,130$.
How old is Jean Bizzari?
Jean Bizzari is 65, he's been the Independent Director of Halozyme Therapeutics since 2015. There are 1 older and 9 younger executives at Halozyme Therapeutics. The oldest executive at Halozyme Therapeutics Inc. is Connie Matsui, 66, who is the Independent Chairman of the Board.
Insiders trading at Halozyme Therapeutics
Over the last 17 years, insiders at Halozyme Therapeutics have traded over 92,345,799$ worth of Halozyme Therapeutics stock and bought 9,720,772 units worth 67,958,365$ . The most active insiders traders include Randal J Kirk、David A Ramsay、Gregory Ian Frost. On average, Halozyme Therapeutics executives and independent directors trade stock every 21 days with the average trade being worth of 3,961,432$. The most recent stock trade was executed by Michael J. La Barre on 27 August 2024, trading 5,580 units of HALO stock currently worth 102,728$.
What does Halozyme Therapeutics do?
we are a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapies that target the tumor microenvironment. our lead proprietary program, investigational drug pegph20, applies a unique approach to targeting solid tumors, potentially providing increased tumor access for co-administered cancer therapies. by breaking down potential barriers to cancer, pegph20 may help make existing treatments more effective by allowing therapies to reach the tumor. we are built on a foundation of value-driving partnerships with leading pharmaceutical companies including, roche, pfizer, janssen, baxalta, abbvie and lilly, for our enhanze™ drug delivery technology platform, which enables biologics and small molecule compounds currently administered intravenously to be delivered subcutaneously. this technology may also allow for more rapid delivery of therapies that are already delivered subcutaneously. we are a diverse team, who are committed to bringing therapies
What does Halozyme Therapeutics's logo look like?
Complete history of Jean Bizzari stock trades at Halozyme Therapeutics、Pieris Pharmaceuticals Inc、Aprea Therapeutics、ADC Therapeutics SA
Halozyme Therapeutics executives and stock owners
Halozyme Therapeutics executives and other stock owners filed with the SEC include:
-
Helen Torley,
President, Chief Executive Officer, Director -
Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.,
Pres, CEO & Director -
Elaine D. Sun,
Sr. VP & CFO -
Dr. Michael J. LaBarre,
Sr. VP & Chief Technical Officer -
Connie Matsui,
Independent Chairman of the Board -
Jeffrey Henderson,
Independent Director -
Kenneth Kelley,
Independent Director -
Matthew Posard,
Independent Director -
Bernadette Connaughton,
Independent Director -
Jean-Pierre Bizzari,
Independent Director -
James Daly,
Independent Director -
Al Kildani,
Vice President, Investor Relations & Corporate Communications -
Elaine Sun,
Chief Financial Officer, Senior Vice President -
Todd Butler,
Chief of Staff to the CEO, VP & Head of Project Management -
Dr. Steve Knowles B.S.,
Chief Medical Officer -
William J. Fallon,
Sr. VP &, Global ENHANZE Program Lead, CMC Operations & Strategic Alliances -
Amy Marinne Fox,
VP of HR -
Mark Snyder,
Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec. -
Albert S. Kildani,
VP of Investor Relations & Corp. Communications -
Ed Gemo,
VP, Chief Information & Security Officer -
Athena Countouriotis,
SVP and Chief Medical Officer -
Kathryn E Falberg,
Director -
Mark J Gergen,
SVP, Chief Operating Officer -
Mark Howard Snyder,
SVP, CHIEF LEGAL OFFICER -
Randal J Kirk,
Director -
Harry J Leonhardt,
SVP, GC and CCO -
Alison A. Armour,
SVP, Research & Development -
John Stuart Patton,
Director -
Robert Engler,
Director -
David A Ramsay,
Secretary, CFO -
William J Fallon,
VP-Manufacturing and Operation -
James P Shaffer,
VP & Chief Commercial Officer -
Jean I Liu,
VP & General Counsel -
Gregory Ian Frost,
VP and Chief Scientific Off. -
H. Michael Shepard,
VP, Chief Scientific Officer -
Kurt A Gustafson,
Vice President and CFO -
Steven T Thornton,
Director -
Jonathan E Lim,
President, CEO -
Richard C Yocum,
VP-Clinical Development -
Jonathan A Leff,
VP, Chief Medical Officer -
Robert J Little,
VP-Chief Commercial Officer -
Don A Kennard,
Vice President, Regulatory Aff -
Matthew Hooper,
Vice Pres & General Counsel -
Benjamin Hickey,
SVP, Chief Commerical Officer -
Laurie Stelzer,
SVP, Chief Financial Officer -
Mahesh Krishnan,
-
Masaru Matsuda,
SVP, General Counsel -
Akiko Moni Miyashita,
-
Michael J. La Barre,
SVP, CHIEF TECHNICAL OFFICER -
Nicole La Brosse,
SVP, CHIEF FINANCIAL OFFICER -
Barbara Gayle Duncan,